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ORIGINAL ARTICLE
T-cell receptor Vb skewing frequently occurs in refractory
cytopenia of childhood and is associated with an expansion of
effector cytotoxic T cells: a prospective study by EWOG-MDS
AM Aalbers1,2, MM van den Heuvel-Eibrink1, I Baumann3, HB Beverloo4, GJ Driessen2,5, M Dworzak6, A Fischer7, G Go¨hring8,
H Hasle9, F Locatelli10, B De Moerloose11, P Noellke7, M Schmugge12, J Stary13, A Yoshimi7, M Zecca14, CM Zwaan1,
JJM van Dongen2, R Pieters1, CM Niemeyer7, VHJ van der Velden2,15 and AW Langerak2,15
Immunosuppressive therapy (IST), consisting of antithymocyte globulin and cyclosporine A, is effective in refractory cytopenia
of childhood (RCC), suggesting that, similar to low-grade myelodysplastic syndromes in adult patients, T lymphocytes are involved
in suppressing hematopoiesis in a subset of RCC patients. However, the potential role of a T-cell-mediated pathophysiology in
RCC remains poorly explored. In a cohort of 92 RCC patients, we prospectively assessed the frequency of T-cell receptor (TCR)
b-chain variable (Vb) domain skewing in bone marrow and peripheral blood by heteroduplex PCR, and analyzed T-cell subsets in
peripheral blood by ﬂow cytometry. TCRVb skewing was present in 40% of RCC patients. TCRVb skewing did not correlate with
bone marrow cellularity, karyotype, transfusion history, HLA-DR15 or the presence of a PNH clone. In 28 patients treated with
IST, TCRVb skewing was not clearly related with treatment response. However, TCRVb skewing did correlate with a disturbed
CD4þ /CD8þ T-cell ratio, a reduction in naive CD8þ T cells, an expansion of effector CD8þ T cells and an increase in activated
CD8þ T cells (deﬁned as HLA-DRþ , CD57þ or CD56þ ). These data suggest that T lymphocytes contribute to RCC pathogenesis in
a proportion of patients, and provide a rationale for treatment with IST in selected patients with RCC.
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INTRODUCTION
Myelodysplastic syndromes (MDS), which are characterized by
clonal hematopoiesis, impaired differentiation and maturation of
myeloid cells, peripheral blood cytopenias and a risk of progression
to acute myeloid leukemia, are rare in childhood, with an estimated
annual incidence of 0.8–1.8 per million children aged 0–14 years.1–3
The most common variant of pediatric MDS is refractory cytopenia
of childhood (RCC), deﬁned as myelodysplasia without an increased
blast count. About 80% of children with RCC have a hypocellular
bone marrow, and karyotype is normal in the majority of patients.4,5
Intrinsic hematopoietic stem cell defects, caused by acquired
cytogenetic and molecular aberrations or by epigenetic changes,
result in hallmark features of MDS.6,7 However, evidence obtained in
adult MDS patients also suggests that a T-cell-mediated immune
response directed against hematopoietic progenitor cells contributes
to MDS pathophysiology. Clinically, immunosuppressive therapy (IST)
consisting of antithymocyte globulin (ATG), which speciﬁcally targets
T cells, with or without cyclosporine A, is effective in selected
patients.8–18 Furthermore, in vitro experiments demonstrated that
autologous peripheral blood lymphocytes of MDS patients inhibit
granulocyte colony formation in a major histocompatibility
complex class I-dependent manner;19–22 this inhibitory effect
was abrogated by ATG in the few patients studied.19
Subsequently, analysis of the T-cell receptor (TCR) b-chain
variable (Vb) domain usage by ﬂow cytometry and PCR-based
methods showed oligoclonal expansions of mainly CD8þ T cells in
MDS patients.19,21,23–26 These clonally expanded T cells were
revealed to have an activated and effector phenotype.21,27–29
We recently reported that cyclosporine A and ATG are effective
in RCC,30 and that over half of RCC patients display a skewed
TCRVb complementarity-determining region 3 (CDR3) usage,31
which is representative of clonal T-cell expansion. These ﬁndings
indicate that an immune-mediated pathophysiology might also be
present in a proportion of RCC patients. However, apart from
the latter studies, the potential role of a T-cell-mediated
pathophysiology in RCC remains unexplored. In a prospective
study conducted by the European Working Group of MDS in
Childhood (EWOG-MDS), we therefore assessed the frequency of
TCRVb skewing in bone marrow and peripheral blood obtained
from a cohort of 92 RCC patients, correlated TCRVb skewing with
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clinical and laboratory characteristics, and analyzed the T-cell
subset composition of peripheral blood. We here describe that
T-cell oligoclonality is frequently present in RCC, correlates with a
disturbed CD4þ /CD8þ T-cell ratio, an expansion of effector CD4þ
and CD8þ T cells, and an activated phenotype of CD8þ T cells.
Altogether, our data suggest that T cells are actively involved in
RCC pathogenesis in a substantial proportion of patients.
MATERIALS AND METHODS
Patients and controls
Peripheral blood samples for PNH analysis were obtained from 92
consecutive, treatment-naive primary RCC patients, p18 years of age
(Table 1). Patients were diagnosed according to World Health Organization
criteria5 between June 2005 and December 2011, enrolled in the
prospective, multicenter studies EWOG-MDS 2006 and EWOG-MDS RC06
(ClinicalTrial.gov identiﬁers: NCT00662090 and NCT00499070). Peripheral
blood and bone marrow samples obtained from 29 pediatric patients
(median age: 13.2 years; range: 2–18) with (very) severe aplastic anemia
((v)SAA) served as controls for TCRVb analysis. Peripheral blood samples
obtained from 152 healthy subjects (age o2 years, n¼ 53; 2–4 years,
n¼ 27; 5–9 years, n¼ 30; 10–15 years, n¼ 20;415 years, n¼ 22) served as
controls for T-cell subset analysis. Further details are described in
Supplementary Methods.
Immunosuppressive therapy
A subset of RCC patients included for TCRVb analysis was treated with IST
consisting of horse or rabbit-ATG, prednisolone and cyclosporine A.
Response to IST was evaluated on day 180. Treatment details and response
criteria are described in Supplementary Methods.
TCRVb analysis by heteroduplex PCR
TCRVb CDR3 repertoire analysis by heteroduplex PCR in mononuclear cells
was performed as previously described.31,32 Skewing was deﬁned when
two or more TCRVb families showed an oligoclonal pattern on
heteroduplex gel. This cutoff was based on healthy controls, in whom
skewing in more than one TCRVb family was present in only 2 of 18 cases
(11%).31 Skewing was further subdivided into weak skewing, when an
oligoclonal pattern was found in 2–5 TCRVb families, and strong skewing,
when an oligoclonal pattern was found in 45 TCRVb families.31 Detailed
methods may be found in Supplementary Methods.
T-cell subset analysis by ﬂow cytometry
Fresh peripheral blood samples were processed, stained and acquired on a
FACSCanto II ﬂow cytometer (BD Biosciences, Erembodegem, Belgium).
Data were analyzed using FlowJo software version 7.6.5 (Tree Star, Ashland,
OR, USA). Lymphocyte subsets were gated and deﬁned as described in
Supplementary Methods, and compared between RCC patients and
healthy controls after categorizing patients and controls into age groups
as previously published (o2, 2–4, 5–9, 10–15, 415 years),33 whereas
lymphocyte and T-cell subset distributions in skewed and non-skewed RCC
patients were compared after normalization according to age group using
Z-scores as described below.
Statistical analyses
Statistical analyses were performed with SPSS 20 (IBM, Chicago, IL, USA)
and GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA).
Categorical variables were compared using the chi-square test or Fisher’s
exact test. Continuous variables were compared using the Mann–Whitney
U-test or the Kruskal–Wallis test when more than two groups were
compared. To compare relative lymphocyte and T-cell subset distributions
between RCC patients with and without a skewed T-cell repertoire, taking
age-dependent changes in into account, Z-scores were calculated as
Z¼ (X–m)/s, with X¼ raw score, m¼mean of age-matched control group,
s¼ s.d. of the age-matched control group. All reported P-values are
two-sided and were considered statistically signiﬁcant when o0.05;
P-values 40.1 were reported as nonsigniﬁcant (NS), whereas those
between 0.05 and 0.1 were reported in detail.
RESULTS
Patient characteristics
A total of 92 treatment-naive RCC patients (46 male, 46 female),
with a median age at diagnosis of 10 years (range: 1–18 years),
were analyzed by heteroduplex PCR for TCRVb CDR3 skewing in
bone marrow and/or peripheral blood. Median time from
diagnosis to TCRVb analysis was 43 days. Clinical characteristics
of the included patients are summarized in Table 1. Hypocellular
bone marrow was reported in 82% of patients, which is
comparable to the previously reported frequency of 81% of
primary RCC patients in an interim analysis of studies EWOG-MDS
1998 and 2006.4 Conventional cytogenetics displayed a normal
karyotype in 67 of 78 patients (86%), which is slightly higher than
the previously reported frequency of 77%;4 monosomy 7 in 5 of 78
patients (including 1 patient with monosomy 7 and additional
aberrations) (6%) and other cytogenetic aberrations in 6 of 78
patients (trisomy 8 in 2 patients, rare aberrations in 3 patients and
del(7q) in 1 patient) (8%). In 12 patients karyotype was not
obtained owing to insufﬁcient metaphases and in 2 patients no
information was available.
TCRVb skewing frequently occurs in bone marrow and peripheral
blood of RCC patients
TCRVb CDR3 skewing in the bone marrow occurred in 31 of 79
RCC patients (39%) who were successfully analyzed. Of the 31
patients with a skewed TCRVb CDR3 usage, 20 (25%) displayed
weak skewing and 11 (14%) strong skewing. In the peripheral
blood, 33 of 83 analyzed RCC patients (40%) showed a skewed
TCRVb usage, 23 (28%) of whom had a weakly skewed and 10
(12%) a strongly skewed repertoire (Table 2). In the 70 RCC
patients successfully analyzed in both bone marrow and
peripheral blood, skewing was similar in bone marrow and
peripheral blood: 29 of 70 patients (41%) displayed weak or strong
skewing in the bone marrow compared with 26 of 70 patients
(37%) in the peripheral blood. The frequency of skewing of
individual TCRVb families in peripheral blood and bone marrow
within all RCC patients is depicted in Figure 1a: there appeared to
be no preferential skewing of speciﬁc TCRVb families and TCRVb
usage was comparable in bone marrow and peripheral blood.
TCRVb skewing occurs less frequently in bone marrow of RCC than
of (v)SAA patients
In a previous pilot study, RCC and (v)SAA patients displayed a
similar frequency of TCRVb skewing in bone marrow and
peripheral blood combined.31 In the present study, we
compared the frequency of TCRVb skewing in (v)SAA with a
larger cohort of RCC patients. TCRVb skewing in the bone marrow,
Table 1. Clinical and laboratory characteristics of included RCC
patients
Characteristic
Number of patients 92
Median age at diagnosis, years (range) 10.3 (1–18)
Male sex, no. (%) 46 (50)
Hypocellular bone marrow, no. (%) 74 of 90 (82)
Cytogenetics, no. (%)a
Normal 67 of 78 (86)
Monosomy 7b 5 of 78 (6)
Otherc 6 of 78 (8)
Abbreviation: RCC, refractory cytopenia of childhood. aIn 12 of 90 patients
(13%) no karyotype was obtained due to insufficient metaphases;
in 2 patients no data were available. bIncludes one patient with monosomy
7 and other aberrations. cIncludes one patient with del(7q), two patients
with trisomy 8 and three patients with rare aberrations.
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but not in the peripheral blood, occurred signiﬁcantly less
frequently in RCC patients than in (v)SAA patients: 48 of 79 RCC
patients (61%) did not display skewing in the bone marrow
compared with only 7 of 20 (v)SAA patients (35%, P¼ 0.038); 20 of
79 RCC patients (25%) versus 10 of 20 (v)SAA patients (50%)
displayed weak skewing in the bone marrow; and 11 of 79 RCC
patients (14%) versus 3 of 20 (15%) of (v)SAA patients had a
strongly skewed TCRVb repertoire in the bone marrow (Table 2).
The frequency of skewing of individual TCRVb families in (v)SAA is
depicted in Figure 1b.
Clinical characteristics of RCC patients with a skewed TCRVb
repertoire
We next compared clinical characteristics of RCC patients with and
without a skewed TCRVb repertoire. Because characteristics of
patients with weak and strong skewing were similar, these
patients were grouped for further analyses (Table 3). Patients
with a skewed usage of the TCRVb in the peripheral blood were
older than patients with a polyclonal T-cell repertoire (median age:
13 versus 10 years, P¼ 0.013). A comparable relationship between
age and skewing of the T-cell repertoire in the bone marrow was
observed, but this difference was not statistically signiﬁcant.
Skewing of the TCRVb repertoire did not correlate with gender,
bone marrow cellularity or transfusion dependency for platelets or
erythrocytes. As the occurrence of trisomy 8 has been linked with
response to IST and the presence of trisomy 8-speciﬁc clonal T-cell
expansions,17,34,35 we compared cytogenetic results among
patients with and without T-cell skewing. The distribution of
patients with a normal karyotype or with monosomy 7 did not
differ among the groups with or without a skewed T-cell
repertoire, neither in bone marrow nor in peripheral blood.
However, all ﬁve patients with other abnormalities in the
karyotype, including both patients with trisomy 8 that were
included in the study, had a skewed T-cell repertoire in the bone
marrow (P¼ 0.014). In the peripheral blood the same trend was
observed, but differences were not statistically signiﬁcant. Finally,
although HLA-DR15 and the presence of minor PNH clones are
predictors of IST response in some studies and thought to be
indicators of a T-cell-mediated pathophysiology of bone marrow
failure,17,36–39 we observed no differences in the frequency of
HLA-DR15 and PNH clone positivity between the groups with and
without skewing.
Laboratory characteristics of RCC patients with a skewed TCRVb
repertoire
RCC patients with or without T-cell skewing in the peripheral
blood had similar peripheral blood leukocyte, neutrophil, lym-
phocyte, T-cell and platelet counts, and comparable hemoglobin
and mean corpuscular volume levels (determined at the time of
peripheral blood and bone marrow collection for TCRVb repertoire
analysis) (data not shown, all P-values 40.01). However, patients
with strong, but not those with weak, skewing in the bone marrow
had signiﬁcantly lower leukocyte, absolute lymphocyte and T-cell
counts in the peripheral blood than patients without skewing
(median leukocyte count, 3.3 109/l (range, 0.8–7.5) versus
2.1 109/l (range, 0.8–2.9); median lymphocyte count, 1.9 109/l
(range, 0.6–6.1) versus 1.1 109/l (0.1–2.2); median T-cell count,
1.2 109/l (range, 0.5–3.6) versus 0.6 109/l (range, 0.4–0.7);
P¼ 0.020, P¼ 0.002 and P¼ 0.020, respectively).
Association of TCRVb repertoire skewing with response to IST
Twenty-eight RCC patients were treated with IST and evaluated for
response at day 180 after the start of therapy. Response to IST was
not signiﬁcantly different between patients with or without T-cell
skewing (Table 3). In particular, 5 of 8 patients (63%) with skewing
in the bone marrow responded to IST, whereas 4 of 13 patients
(31%) without skewing in the bone marrow responded to IST; 6 of
10 patients (60%) with skewing in the peripheral blood responded
to IST, whereas 8 of 16 patients (50%) without skewing in the
peripheral blood responded to IST. Furthermore, there were no
signiﬁcant differences in the frequency of skewing of speciﬁc
TCRVb families (data not shown) and in the median total
Table 2. Frequency of TCRVb CDR3 skewing in RCC and (v)SAA patients
RCC (v)SAA P
Bone marrow skewing, no. (%)
No skewing (0–1 families skewed) 48 of 79 (61) 7 of 20 (35) 0.038a
Weak skewing (2–5 families skewed) 20 of 79 (25) 10 of 20 (50)
Strong skewing (45 families skewed) 11 of 79 (14) 3 of 20 (15)
Peripheral blood, no. (%)
No skewing (0–1 families skewed) 50 of 83 (60) 17 of 28 (61) NSa
Weak skewing (2–5 families skewed) 23 of 83 (28) 8 of 28 (29)
Strong skewing (45 families skewed) 10 of 83 (12) 3 of 28 (11)
Abbreviations: CDR3, complementarity-determining region 3; NS, nonsignificant; RCC, refractory cytopenia of childhood; TCRVb, T-cell receptor b-chain
variable; (v)SAA, (very) severe aplastic anemia. aNo skewing versus weak or strong skewing; chi-square test. Bold indicates P-value o0.05.
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Figure 1. Frequency of skewing of individual TCRVb families in
bone marrow and peripheral blood of RCC and (v)SAA patients.
(a) Frequency of skewing in RCC patients. (b) Frequency of skewing
in (v)SAA patients.
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number of skewed TCRVb families among IST responding and
nonresponding RCC patients (medians of 2 and 0.5 expanded
families in the bone marrow, respectively, and 1 and 0.5 in the
peripheral blood, respectively). In responding and nonresponding
patients in whom follow-up bone marrow or peripheral blood
samples were available (11 responders, median follow-up time
after start of IST: 367 days (range: 234–1233 days); and 8 non-
responders, median follow-up time after start of IST: 160 days
(range: 62–1018 days)), no consistent increases or decreases
in the number of skewed TCRVb families were observed (data not
shown).
TCRVb skewing is associated with a reduction of naive CD8þ
T cells and an expansion of effector CD4þ and CD8þ T cells in
peripheral blood
Previous studies have shown that adult MDS patients, in
comparison with healthy controls, display a disturbed CD4þ /CD8þ
T-cell ratio29 and a reduction in naive CD8þ T cells with an
increase in CD8þ effector cells.21,25,29 In the present RCC cohort,
we therefore compared the relative distribution of these
parameters with healthy children. RCC patients showed a strong
relative expansion of lymphocytes (Supplementary Figure S1),
mainly due to an absolute reduction in granulocytes and
monocytes (data not shown). Within the lymphocytes, T cells
were relatively increased (Supplementary Figure S1), mainly due
to an absolute reduction in B cells and natural killer cells
(Supplementary Figure S2). Within the T-cell compartment, no
consistent differences were observed in the frequency of CD4þ
and CD8þ T cells and in the distribution of naive and effector
CD4þ and CD8þ T cells (Supplementary Figure S1) between RCC
patients and healthy children. However, RCC patients with a
skewed TCRVb repertoire in the bone marrow had signiﬁcantly
less naive CD8þCD45ROCD27þ T cells and more terminally
differentiated effector CD8þCD45ROCD27 T cells in the
peripheral blood than RCC patients without a skewed T-cell
repertoire (Figure 2 and Supplementary Table S1). Moreover, when
compared with RCC patients without skewing, patients with a
skewed T-cell repertoire in the peripheral blood showed
signiﬁcantly different relative peripheral blood T-cell subset
numbers, with less CD4þ T cells, more CD8þ T cells and
consequently a decreased CD4þ /CD8þ T-cell ratio, more termin-
ally differentiated effector CD4þCD45ROCD27 T cells, less
naive CD8þCD45ROCD27þ T cells, more effector memory
CD8þCD45ROþCD27 T cells and more terminally differentiated
effector CD8þCD45ROCD27 T cells (Figure 2; medians, ranges
and P-values are shown in Supplementary Table S1). The relative
number of terminally differentiated effector CD8þCD45RO
CD27 T cells showed an inverse correlation with the relative
number of naive CD8þCD45ROCD27þ T cells, irrespective of
TCRVb skewing (Pearson’s r¼  0.557, P¼ 0.000).
TCRVb skewing is associated with an expansion of activated CD8þ
T cells in peripheral blood
When compared with healthy pediatric controls, no consistent
differences were observed in the frequency of activated CD8þ
T cells in RCC patients (Supplementary Figure S3). However, the
frequency of CD8þ T cells positive for activation markers CD56
and CD57 in patients with a skewed TCRVb repertoire in the bone
marrow and peripheral blood, and HLA-DR in patients with a
skewed TCRVb repertoire in the bone marrow, was signiﬁcantly
increased when compared with patients with a polyclonal T-cell
repertoire (Figures 3a–c, Supplementary Table S2). No differences
were observed in the frequency of CD8þ T cells positive for the
activation marker CD38 (Figure 3d; medians, ranges and P-values
are shown in Supplementary Table S2).
DISCUSSION
In this study we show that TCRVb skewing occurs in about 40% of
RCC patients, suggesting an immune-mediated suppression of
hematopoiesis in a considerable proportion of these patients. The
frequency of TCRVb skewing in the bone marrow, but not in the
peripheral blood, of RCC patients was lower than the frequency of
65% in pediatric (v)SAA patients, indicating that an immune-
mediated pathophysiology of bone marrow failure might be more
common in (v)SAA than in RCC. Distinguishing RCC from (v)SAA,
Table 3. Clinical characteristics of RCC patients without or with a skewed TCRVb repertoire in BM or PB
TCRVb skewing BM TCRVb skewing PB
No skewing Skewing P No skewing Skewing P
Number of patients 48 31 50 33
Median age at diagnosis, years (range) 10 (1–18) 13 (1–18) NS 10 (1–18) 13 (4–18) 0.013
Male sex, no. (%) 22 of 48 (46) 16 of 31 (52) NS 27 of 50 (46) 15 of 33 (46) NS
Hypocellular bone marrow, no. (%) 35 of 47 (75) 26 of 30 (87) NS 40 of 49 (82) 29 of 33 (88) NS
Transfusion dependency at TCRVb analysis, no. (%)
Platelets 15 of 32 (47) 9 of 18 (50) NS 16 of 32 (50) 9 of 18 (50) NS
Erythrocytes 12 of 32 (38) 6 of 18 (33) NS 12 of 32 (38) 7 of 18 (39) NS
Cytogenetics, no. (%)
Normal 35 of 38 (92) 23 of 30 (77) 0.094 34 of 38 (90) 26 of 32 (81) NS
Monosomy 7 3 of 38 (8) 2 of 30 (7) NS 3 of 38 (8) 1 of 32 (3) NS
Other 0 of 38 (0) 5 of 30 (17) 0.014 1 of 38 (3) 5 of 32 (16) 0.086
HLA-DR15, no. (%) 13 of 37 (35) 6 of 23 (26) NS 10 of 39 (26) 10 of 28 (36) NS
PNH clone at diagnosis, no. (%)
40.01% 17 of 43 (40) 14 of 30 (47) NS 20 of 48 (42) 13 of 33 (40) NS
40.1% 10 of 43 (23) 7 of 30 (23) NS 13 of 48 (27) 8 of 33 (24) NS
Response to IST, no. (%) 4 of 13 (31) 5 of 8 (63) NS 8 of 16 (50) 6 of 10 (60) NS
Abbreviations: BM, bone marrow; IST, immunosuppressive therapy; NS, nonsignificant; PB, peripheral blood; RCC, refractory cytopenia of childhood;
TCRVb, T-cell receptor b-chain variable. Bold indicates P-value o0.05.
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however, can be challenging, mainly due to the high frequency of
bone marrow hypocellularity and the low frequency of karyotypic
abnormalities in RCC, and a pathophysiological overlap between
both diseases seems likely.
TCRVb skewing was most prevalent in older children, but no
correlation was found between skewing and bone marrow
cellularity, the presence or absence of a normal karyotype or
transfusion history. Previous reports in adult MDS patients
also failed to show any signiﬁcant correlation between clinical
characteristics and TCRVb skewing.25,26 With respect to laboratory
characteristics, we observed no difference in hemoglobin or mean
corpuscular volume levels, platelet, leukocyte, absolute neutrophil,
lymphocyte and T-cell counts when patients with TCRVb skewing
were compared with those without skewing, which is in line with
reports in adult MDS patients.25,26 However, patients with skewing
in45 TCRVb families had signiﬁcantly lower absolute lymphocyte
and T-cell counts than patients without skewing. This indicates
that in patients with strong TCRVb skewing, but not in patients
with skewing in 2–5 TCRVb families, skewing might reﬂect a
contracted T-cell repertoire. This phenomenon was previously
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differentiated effector CD8þ T cells. Lines indicate medians. Z-scoreso0 indicate a decrease and Z-scores40 indicate an increase compared
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described in aplastic anemia patients after IST.40 Furthermore,
although HLA-DR15 positivity and the presence of a PNH clone are
thought to be indicators of an immune-mediated pathophysiology
of MDS, we did not ﬁnd an increased frequency of TCRVb skewing
in HLA-DR15- or PNH-positive patients.
TCRVb skewing was not predictive of IST response in the
present pediatric cohort. Although the number of patients treated
with IST was small, and results should be interpreted cautiously,
this is consistent with studies in adult MDS patients, in whom a
predictive role of TCRVb skewing for IST response has not been
found.23,25,26 Nevertheless, alterations in TCRVb proﬁles or loss of
clonal dominance of speciﬁc TCRVb families after response to IST
were described.19,24 Likely, the speciﬁc T-cell subsets (for example,
FOXP3þ regulatory T cells, Th17 T cells)41–44 involved in the clonal
expansion, the type of IST the patient received and patient
characteristics, such as age, HLA-type, bone marrow cellularity and
underlying molecular aberrations, all modulate response to IST and
TCRVb skewing alone is insufﬁcient to predict response to therapy.
TCRVb skewing was associated with a reduced CD4þ /CD8þ
T-cell ratio in peripheral blood, a reduction in naive CD8þ T cells,
an expansion of effector CD8þ T cells and an increase in activated
CD8þ T cells. Owing to a limited availability of material, regulatory
T cells and Th17 T cells could not be assayed. However, our data
conﬁrm that RCC patients with a skewed TCRVb repertoire indeed
have an expanded population of activated T cells that might
mediate suppression of hematopoiesis in RCC. A limitation of our
study is that we did not provide direct evidence that T cells indeed
suppress hematopoiesis. Future studies could employ coculture
experiments with clonally expanded T cells and autologous
myeloid (progenitor) cells, using adequate controls, to support
the hypothesis that hematopoiesis in RCC is inhibited in a T-cell-
dependent manner. Yet, the limited numbers of myeloid
(progenitor) cells in RCC bone marrow might hamper these
experiments.
The exact meaning of TCRVb skewing and expansion of
activated effector CD8þ T cells, and presumed T-cell-mediated
suppression of hematopoiesis in MDS, remains unclear. It might
either be a reﬂection of immune surveillance against hemato-
poietic cells expressing a neo-antigen or might be a result of
breaking of self-tolerance leading to an autoimmune-like response
against normal hematopoietic progenitor cells, or a combination
of both. Evidence for the latter hypothesis was provided in the
speciﬁc subgroup of MDS patients with trisomy 8, who are likely to
respond to IST, but in whom the proportion of trisomy 8 cells
increases after IST response.17,34 T cells of clonally expanded
TCRVb families obtained from these patients selectively inhibited
trisomy 8 cell growth.34 WT1, overexpressed in trisomy 8-positive
bone marrow mononuclear cells, but also expressed at a low
level in normal hematopoietic stem cells, was subsequently
implicated to be one of the antigens inducing T-cell-mediated
myelosuppression in trisomy 8-positive MDS.35 Future efforts to
gain more insight into the precise nature and antigenic target(s) of
the skewed and activated T cells in trisomy 8-positive and other
subtypes of MDS could beneﬁt from TCR repertoire deep
sequencing approaches, which have now become readily
available. These approaches should preferably be performed in
sorted T-cell subsets, taking into account differences between
human leukocyte antigen types.
In summary, we show that TCRVb skewing is frequently
detected in RCC. TCRVb skewing is associated with a disturbed
CD4þ /CD8þ T-cell ratio, an expansion of effector CD4þ and
CD8þ T cells, and an activated phenotype of CD8þ T cells. These
data, in conjunction with the previously described response to IST
in RCC patients,30 suggest that T cells are involved in the
pathogenesis of RCC in a proportion of patients, and provide
a rationale for treatment with IST in selected patients with
RCC according to the existing treatment recommendations by
EWOG-MDS.30
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